MedTrace Logo

Comparing Efficacy of Bromfenac 0.09%, Nepafenac 0.3% and Diclofenac 0.1% in Patients After Cataract Surgery

NCT07178639 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2025-09-17

No results posted yet for this study

Summary

The goal of this clinical trial is to learn which of the drugs bromfenac 0.09%, nepafenac 0.3% and diclofenac 0.1% has better efficacy in treatment and prevention of cystoid macular oedema after cataract surgery.

The main questions it aims to answer are:

Which of the drugs has better efficacy in macular oedema prevention? What medical problems do participants have when taking different drugs? Researchers will compare drugs to each other.

Participants will:

Take on of the drugs (randomized) as their treatment in preoperative and postoperative period.

Visit the clinic after the surgery on the first day, first week, in three weeks and in six weeks.

Undergo retina examination with OCT (optical coherence tomography), best vision, and fill in forms considering their quality of life.

Conditions

  • Macular Oedema
  • Cataract Surgery
  • NSAID (Non-Steroidal Anti-Inflammatory Drug)

Interventions

DRUG

Bromfenac 0.09 % Ophthalmic Solution

Comparison of bromfenac ophthalmic solution 0.09% twice per day vs. nepafenac ophthalmic suspension 0.3% once per day vs. diclofenac ophthalmic suspension 0.1% four times per day for prevention of cystoid macular oedema associated with cataract surgery.

DRUG

Nepafenac 0.3% Oph Susp

Comparison of bromfenac ophthalmic solution 0.09% twice per day vs. nepafenac ophthalmic suspension 0.3% once per day vs. diclofenac ophthalmic suspension 0.1% four times per day for prevention of cystoid macular oedema associated with cataract surgery.

DRUG

diclofenac 0.1% ophthalmic susp.

Comparison of bromfenac ophthalmic solution 0.09% twice per day vs. nepafenac ophthalmic suspension 0.3% once per day vs. diclofenac ophthalmic suspension 0.1% four times per day for prevention of cystoid macular oedema associated with cataract surgery.

Sponsors & Collaborators

  • Nemocnice Kolín

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-08-01
Primary Completion
2026-02-28
Completion
2026-02-28

Countries

  • Czechia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07178639 on ClinicalTrials.gov